Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Obseva Sa (OBSV)

Obseva Sa (OBSV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,937
  • Shares Outstanding, K 77,971
  • Annual Sales, $ 20,110 K
  • Annual Income, $ -58,380 K
  • 60-Month Beta 0.68
  • Price/Sales 0.93
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OBSV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings $-0.13 on 12/01/22
  • Latest Earnings Date 03/23/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0800 +27.25%
on 02/24/23
0.2865 -64.47%
on 03/03/23
-0.0731 (-41.80%)
since 02/22/23
3-Month
0.0800 +27.25%
on 02/24/23
0.2865 -64.47%
on 03/03/23
-0.0453 (-30.80%)
since 12/22/22
52-Week
0.0800 +27.25%
on 02/24/23
2.1400 -95.24%
on 06/06/22
-1.2182 (-92.29%)
since 03/22/22

Most Recent Stories

More News
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates

ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OBSV : 0.1018 (-15.52%)
USAQ : 0.0869 (-13.10%)
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy

ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OBSV : 0.1018 (-15.52%)
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...

OBSV : 0.1018 (-15.52%)
ObsEva Announces Management Change

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – July 29, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...

OBSV : 0.1018 (-15.52%)
ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...

OBSV : 0.1018 (-15.52%)
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

  -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- ...

OBSV : 0.1018 (-15.52%)
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ALKS : 27.07 (-0.66%)
ABEO : 7.25 (-1.23%)
OBSV : 0.1018 (-15.52%)
SESN : 12.5760 (+7.29%)
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy-   ...

OBSV : 0.1018 (-15.52%)
ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...

OBSV : 0.1018 (-15.52%)
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International...

OBSV : 0.1018 (-15.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland.

See More

Key Turning Points

3rd Resistance Point 0.1404
2nd Resistance Point 0.1319
1st Resistance Point 0.1169
Last Price 0.1018
1st Support Level 0.0934
2nd Support Level 0.0849
3rd Support Level 0.0699

See More

52-Week High 2.1400
Fibonacci 61.8% 1.3531
Fibonacci 50% 1.1100
Fibonacci 38.2% 0.8669
Last Price 0.1018
52-Week Low 0.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar